2021

July

Celon Pharma has completed its book - building process. Investors will be taking over all Offered Shares.

Read more...

Celon Pharma S.A. launches public offering of D-series shares

Read more...

June

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes.

Read more...

May

Dynamic export and continuation of positive trends in the development of innovative products

Read more...

February

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor.

Read more...

January

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Read more...

2019

February

Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.

Read more...

2018

November

Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor

Read more...

January

Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial

Read more...

2017

November

Celon Pharma has positively concluded the decentralised procedure (DCP) for Salmex on Scandinavian markets

Read more...

Celon Pharma S.A. begins a clinical programme for Esketamine in the treatment of drug-resistant depression

Read more...

Stable business foundation with a good prospect for presence in new European markets.

Read more...

September

Steady income and positive sales dynamics of Celon Pharma S.A. in the first half of 2017

Read more...

July

Celon Pharma S.A. submitted an application for a permit to build a Research and Development Centre in Kazuń Nowy.

Read more...

Celon Pharma S.A. received a positive assessment and funding recommendation from the National Centre for Research and Development (NCBiR) for 3 projects of developing innovative medicinal products

Read more...

May

Celon Pharma S.A. reports a stable first quarter of 2017 and its plans for the dynamic development of the Company's operations in the current year.

Read more...

A new Research and Development Centre of Celon Pharma S.A.

Read more...

Global commercialisation of Celon Pharma S.A.’s innovative portfolio

Read more...

April

Celon Pharma S.A. reports a steadily growing revenue and profit for 2016

Read more...

February

Celon Pharma S.A. received an award for the best stock debut in 2016

Read more...